Photocure ASA Logo

Photocure ASA

PHO.OL

(0.5)
Stock Price

52,80 NOK

2.83% ROA

2.66% ROE

109.33x PER

Market Cap.

1.404.074.120,00 NOK

24.62% DER

0% Yield

2.5% NPM

Photocure ASA Stock Analysis

Photocure ASA Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Photocure ASA Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

2 ROE

Negative ROE (-8.33%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (-8.84%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

4 PBV

The stock's high Price-to-Book Value (P/BV) ratio (3.11x) suggests it's overvalued, potentially making it an expensive investment.

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-435), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Photocure ASA Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Photocure ASA Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Photocure ASA Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Photocure ASA Revenue
Year Revenue Growth
2002 25.223.000
2003 55.154.000 54.27%
2004 77.809.000 29.12%
2005 53.641.000 -45.06%
2006 210.320.000 74.5%
2007 99.006.000 -112.43%
2008 102.220.000 3.14%
2009 48.428.000 -111.08%
2010 177.357.000 72.69%
2011 115.568.000 -53.47%
2012 133.823.000 13.64%
2013 83.616.000 -60.04%
2014 128.952.000 35.16%
2015 134.717.000 4.28%
2016 143.627.000 6.2%
2017 150.911.000 4.83%
2018 181.510.000 16.86%
2019 281.556.000 35.53%
2020 256.482.000 -9.78%
2021 360.540.000 28.86%
2022 393.132.000 8.29%
2023 430.192.000 8.61%
2023 500.657.000 14.07%
2024 581.792.000 13.95%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Photocure ASA Research and Development Expenses
Year Research and Development Expenses Growth
2002 0
2003 0 0%
2004 31.718.000 100%
2005 38.238.000 17.05%
2006 38.200.000 -0.1%
2007 112.098.000 65.92%
2008 84.303.000 -32.97%
2009 78.980.000 -6.74%
2010 90.167.000 12.41%
2011 66.192.000 -36.22%
2012 50.083.000 -32.16%
2013 33.976.000 -47.41%
2014 32.554.000 -4.37%
2015 31.337.000 -3.88%
2016 22.962.000 -36.47%
2017 32.591.000 29.54%
2018 19.145.000 -70.23%
2019 13.644.000 -40.32%
2020 13.838.000 1.4%
2021 4.322.000 -220.18%
2022 3.342.000 -29.32%
2023 3.808.000 12.24%
2023 2.069.999 -83.96%
2024 4.404.000 53%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Photocure ASA General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 0
2003 0 0%
2004 -10.092.000 100%
2005 -7.137.000 -41.4%
2006 -8.946.000 20.22%
2007 0 0%
2008 8.607.000 100%
2009 9.452.000 8.94%
2010 8.675.000 -8.96%
2011 11.180.000 22.41%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 -15.072.000 100%
2024 -14.808.000 -1.78%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Photocure ASA EBITDA
Year EBITDA Growth
2002 -108.257.000
2003 -51.978.000 -108.27%
2004 -48.286.000 -7.65%
2005 -52.518.000 8.06%
2006 80.411.000 165.31%
2007 -86.061.000 193.43%
2008 -46.725.000 -84.19%
2009 -61.499.000 24.02%
2010 23.986.000 356.4%
2011 -43.964.000 154.56%
2012 -29.397.000 -49.55%
2013 -61.688.000 52.35%
2014 3.000.000 2156.27%
2015 -8.793.000 134.12%
2016 -35.288.000 75.08%
2017 -33.095.000 -6.63%
2018 3.707.000 992.77%
2019 58.950.000 93.71%
2020 5.948.000 -891.09%
2021 33.517.000 82.25%
2022 -20.194.000 265.98%
2023 39.796.000 150.74%
2023 152.582.000 73.92%
2024 198.864.000 23.27%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Photocure ASA Gross Profit
Year Gross Profit Growth
2002 19.391.000
2003 45.640.000 57.51%
2004 64.743.000 29.51%
2005 40.211.000 -61.01%
2006 188.069.000 78.62%
2007 81.680.000 -130.25%
2008 83.146.000 1.76%
2009 42.887.000 -93.87%
2010 168.233.000 74.51%
2011 104.496.000 -60.99%
2012 124.418.000 16.01%
2013 76.787.000 -62.03%
2014 121.956.000 37.04%
2015 126.496.000 3.59%
2016 134.290.000 5.8%
2017 138.900.000 3.32%
2018 164.363.000 15.49%
2019 259.044.000 36.55%
2020 237.971.000 -8.86%
2021 336.490.000 29.28%
2022 370.435.000 9.16%
2023 402.608.000 7.99%
2023 446.833.000 9.9%
2024 522.508.000 14.48%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Photocure ASA Net Profit
Year Net Profit Growth
2002 -96.005.000
2003 -42.767.000 -124.48%
2004 -45.031.000 5.03%
2005 -38.210.000 -17.85%
2006 85.082.000 144.91%
2007 -74.970.000 213.49%
2008 -64.382.000 -16.45%
2009 312.382.000 120.61%
2010 18.092.000 -1626.63%
2011 -7.512.000 340.84%
2012 -47.901.000 84.32%
2013 -58.950.000 18.74%
2014 -24.700.000 -138.66%
2015 -36.178.000 31.73%
2016 35.309.000 202.46%
2017 -34.697.000 201.76%
2018 -36.708.000 5.48%
2019 31.832.000 215.32%
2020 -22.403.000 242.09%
2021 -30.897.000 27.49%
2022 -71.857.000 57%
2023 -19.152.000 -275.19%
2023 267.000 7273.03%
2024 49.328.000 99.46%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Photocure ASA Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 -6
2003 -2 -150%
2004 -3 0%
2005 -2 0%
2006 4 166.67%
2007 -3 200%
2008 -3 -50%
2009 14 114.29%
2010 1 0%
2011 0 0%
2012 -2 100%
2013 -3 0%
2014 -1 -100%
2015 -2 0%
2016 2 200%
2017 -2 200%
2018 -2 0%
2019 1 200%
2020 -1 0%
2021 -1 100%
2022 -3 50%
2023 -1 0%
2023 0 0%
2024 2 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Photocure ASA Free Cashflow
Year Free Cashflow Growth
2002 -54.793.000
2003 -70.887.000 22.7%
2004 -50.677.000 -39.88%
2005 -72.641.000 30.24%
2006 64.741.000 212.2%
2007 -98.796.000 165.53%
2008 -61.660.000 -60.23%
2009 316.801.000 119.46%
2010 -3.004.000 10645.97%
2011 -38.186.000 92.13%
2012 -56.237.000 32.1%
2013 -100.877.000 44.25%
2014 -7.044.000 -1332.1%
2015 -35.965.000 80.41%
2016 -2.909.000 -1136.34%
2017 -42.181.000 93.1%
2018 -26.313.000 -60.3%
2019 19.418.000 235.51%
2020 13.980.000 -38.9%
2021 20.183.000 30.73%
2022 -5.627.000 458.68%
2023 2.781.000 302.34%
2023 47.714.000 94.17%
2024 23.304.000 -104.75%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Photocure ASA Operating Cashflow
Year Operating Cashflow Growth
2002 -50.906.000
2003 -70.506.000 27.8%
2004 -50.248.000 -40.32%
2005 -70.540.000 28.77%
2006 66.326.000 206.35%
2007 -95.655.000 169.34%
2008 -59.677.000 -60.29%
2009 317.444.000 118.8%
2010 15.597.000 -1935.29%
2011 -34.466.000 145.25%
2012 -54.928.000 37.25%
2013 -99.722.000 44.92%
2014 -6.088.000 -1538.01%
2015 -21.032.000 71.05%
2016 19.193.000 209.58%
2017 -23.593.000 181.35%
2018 -24.124.000 2.2%
2019 20.655.000 216.79%
2020 15.585.000 -32.53%
2021 23.886.000 34.75%
2022 -2.018.000 1283.65%
2023 8.669.000 123.28%
2023 60.020.000 85.56%
2024 26.127.000 -129.72%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Photocure ASA Capital Expenditure
Year Capital Expenditure Growth
2002 3.887.000
2003 381.000 -920.21%
2004 429.000 11.19%
2005 2.101.000 79.58%
2006 1.585.000 -32.56%
2007 3.141.000 49.54%
2008 1.983.000 -58.4%
2009 643.000 -208.4%
2010 18.601.000 96.54%
2011 3.720.000 -400.03%
2012 1.309.000 -184.19%
2013 1.155.000 -13.33%
2014 956.000 -20.82%
2015 14.933.000 93.6%
2016 22.102.000 32.44%
2017 18.588.000 -18.9%
2018 2.189.000 -749.15%
2019 1.237.000 -76.96%
2020 1.605.000 22.93%
2021 3.703.000 56.66%
2022 3.609.000 -2.6%
2023 5.888.000 38.71%
2023 12.306.000 52.15%
2024 2.823.000 -335.92%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Photocure ASA Equity
Year Equity Growth
2002 166.999.000
2003 131.444.000 -27.05%
2004 85.566.000 -53.62%
2005 48.465.000 -76.55%
2006 326.935.000 85.18%
2007 259.503.000 -25.99%
2008 199.694.000 -29.95%
2009 415.783.000 51.97%
2010 458.854.000 9.39%
2011 439.337.000 -4.44%
2012 380.268.000 -15.53%
2013 269.123.000 -41.3%
2014 240.058.000 -12.11%
2015 210.060.000 -14.28%
2016 251.943.000 16.62%
2017 218.080.000 -15.53%
2018 176.343.000 -23.67%
2019 208.590.000 15.46%
2020 508.132.000 58.95%
2021 502.633.000 -1.09%
2022 462.733.000 -8.62%
2023 468.942.000 1.32%
2023 482.137.000 2.74%
2024 499.665.000 3.51%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Photocure ASA Assets
Year Assets Growth
2002 299.006.000
2003 233.402.000 -28.11%
2004 173.711.000 -34.36%
2005 105.704.000 -64.34%
2006 375.423.000 71.84%
2007 301.394.000 -24.56%
2008 237.846.000 -26.72%
2009 456.862.000 47.94%
2010 513.842.000 11.09%
2011 509.183.000 -0.91%
2012 432.978.000 -17.6%
2013 301.726.000 -43.5%
2014 270.579.000 -11.51%
2015 248.058.000 -9.08%
2016 285.851.000 13.22%
2017 263.099.000 -8.65%
2018 231.196.000 -13.8%
2019 257.352.000 10.16%
2020 776.047.000 66.84%
2021 789.648.000 1.72%
2022 719.034.000 -9.82%
2023 705.603.000 -1.9%
2023 711.264.000 0.8%
2024 713.582.000 0.32%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Photocure ASA Liabilities
Year Liabilities Growth
2002 132.007.000
2003 101.505.000 -30.05%
2004 88.145.000 -15.16%
2005 57.239.000 -53.99%
2006 48.488.000 -18.05%
2007 41.400.000 -17.12%
2008 38.152.000 -8.51%
2009 41.079.000 7.13%
2010 54.988.000 25.29%
2011 69.846.000 21.27%
2012 52.710.000 -32.51%
2013 32.603.000 -61.67%
2014 30.521.000 -6.82%
2015 37.998.000 19.68%
2016 33.908.000 -12.06%
2017 45.019.000 24.68%
2018 54.853.000 17.93%
2019 48.762.000 -12.49%
2020 267.915.000 81.8%
2021 287.015.000 6.65%
2022 256.301.000 -11.98%
2023 236.661.000 -8.3%
2023 205.217.000 -15.32%
2024 213.917.000 4.07%

Photocure ASA Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
18.95
Net Income per Share
0.47
Price to Earning Ratio
109.33x
Price To Sales Ratio
2.73x
POCF Ratio
20.97
PFCF Ratio
26.9
Price to Book Ratio
2.81
EV to Sales
2.49
EV Over EBITDA
9.07
EV to Operating CashFlow
19.11
EV to FreeCashFlow
24.51
Earnings Yield
0.01
FreeCashFlow Yield
0.04
Market Cap
1,40 Bil.
Enterprise Value
1,28 Bil.
Graham Number
14.02
Graham NetNet
4.98

Income Statement Metrics

Net Income per Share
0.47
Income Quality
8.11
ROE
0.03
Return On Assets
0.02
Return On Capital Employed
0.17
Net Income per EBT
0.64
EBT Per Ebit
0.18
Ebit per Revenue
0.22
Effective Tax Rate
0.39

Margins

Sales, General, & Administrative to Revenue
-0.02
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0.04
Gross Profit Margin
0.9
Operating Profit Margin
0.22
Pretax Profit Margin
0.04
Net Profit Margin
0.03

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
2.47
Free CashFlow per Share
1.93
Capex to Operating CashFlow
0.22
Capex to Revenue
0.03
Capex to Depreciation
0.51
Return on Invested Capital
0.11
Return on Tangible Assets
0.03
Days Sales Outstanding
61.08
Days Payables Outstanding
118.54
Days of Inventory on Hand
253.83
Receivables Turnover
5.98
Payables Turnover
3.08
Inventory Turnover
1.44
Capex per Share
0.54

Balance Sheet

Cash per Share
9,85
Book Value per Share
18,43
Tangible Book Value per Share
8.82
Shareholders Equity per Share
18.43
Interest Debt per Share
5.65
Debt to Equity
0.25
Debt to Assets
0.17
Net Debt to EBITDA
-0.88
Current Ratio
5.82
Tangible Asset Value
0,24 Bil.
Net Current Asset Value
0,17 Bil.
Invested Capital
605092001
Working Capital
0,32 Bil.
Intangibles to Total Assets
0.37
Average Receivables
0,09 Bil.
Average Payables
0,01 Bil.
Average Inventory
34004500
Debt to Market Cap
0.09

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Photocure ASA Dividends
Year Dividends Growth
2009 4
2013 2 -100%

Photocure ASA Profile

About Photocure ASA

Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.

CEO
Mr. Daniel Schneider
Employee
102
Address
Hoffsveien 4
Oslo, 0275

Photocure ASA Executives & BODs

Photocure ASA Executives & BODs
# Name Age
1 Mr. David Moskowitz
Head of Investor Relations
70
2 Mr. Erik Dahl
Chief Financial Officer
70
3 Dr. Anders Neijber M.D.
Chief Medical Officer of Global Medical Affairs, Clinical Development and R&D
70
4 Mr. Tolv Hillestad
Group Controller
70
5 Anja Gossens-von der Heidt
Head of Global Human Resources
70
6 Mr. Daniel Schneider
President & Chief Executive Officer
70

Photocure ASA Competitors